<DOC>
	<DOCNO>NCT01081405</DOCNO>
	<brief_summary>To exploit curative potential allografting , ultimate clinical goal separate GVL GVHD . In murine preclinical model , recipient allogeneic hematopoietic cell transplant preparative regimen total lymphoid irradiation ( TLI ) antithymocyte globulin ( ATG ) develop GVHD . The murine TLI/ATG study turn clinical phase I protocol patient hematological malignancy , reduction acute GVHD &lt; 3 % observe ( Lowsky R et al , N Engl J Med ) . This suggest specific immune mechanism control GVHD preserve GVL . The study include patient lympho myeloproliferative disease . The condition regimen consist TLI [ ten 80 cGy fraction day -11 day -7 day -4 day -1 ; radiation field ( four fieldsâ€”two anterior two posterior ) involve major lymphoid organs include thymus , spleen lymph node ] ATG ( five i.v . dose 1.5 mg/kg/day day -11 day -7 ) . G-CSF mobilise hematopoietic cell , collect day -1 0 , HLA-identical sibling unrelated donor infuse day 0 . Post-transplant immunosuppression consist oral cyclosporine ( 6.25 mg/kg/d ) day -3 micophenolate mophetile ( 15 mg/Kg bid ) day +1 . The clinical primary objective reduce incidence GVHD &lt; 5 % , good survival quality life .</brief_summary>
	<brief_title>Total Lymphoid Irradiation Anti-Thymocyte Globulin Allogeneic Hematopoietic Cell Transplantation</brief_title>
	<detailed_description>PATIENT ENROLMENT . It expect 15 patient / year enrol phase I-II protocol . Patient selection base follow criterion : Eligibility Criteria : 1 . Any patient one follow lympho myeloproliferative malignancy syndromes allogeneic NST warrant . Patients select malignancies/disorders may also consider must approve transplant team Principal Investigator . 2 . Patient age &gt; 50 year , patient &lt; 50 year age pre-existing medical condition prior therapy consider high risk regimen-related toxicity associate conventional myeloablative transplant . 3. HLA-identical sibling match unrelated donor available . Patients one antigen mismatch donor consider discussion transplant team Principal Investigator . STEM CELL TRANSPLANTATION : ( A ) TLI Administration : see `` brief description '' ( B ) ATG : Thymoglobulin administer five time intravenously 1.5 mg/kg/day day -11 day -7 total dose 7.5 mg/kg . Thymoglobulin dos base adjusted ideal body weight . Premedication thymoglobulin include solumedrol 1.0 mg/kg . Mobilized PBPC : The minimum cell dos ( base recipient body weight ) transplant &gt; 5x106 CD34+ cells/kg . Cells collect day -1 0 pool processed infusion day 0 . Fresh cell ( frozen ) infuse . For related donor transplant , target cell dose achieve third apheresis procedure may perform day+1 cell infused day . Collection cell unrelated donor transplant coordinate Italian bone Marrow Transplant Registry subject rule Program . If mobilize PBPC available certain collection center bone marrow use . ( F ) Cyclosporine ( CSP ) : CSP give 6.25 mg/kg p.o . b.i.d ( 9 a.m 9 p.m. ) day -3 day +56 chimerism result obtain . CSP taper day +56 chimerism result obtain . If day +56 chimerism result show &gt; 40 % donor cell CD3+ lineage , patient without evidence GVHD CSP taper begin . The CSP taper 6 % every week . Modifications taper schedule may indicate significant disease progression occur early post-transplantation patient develop GVHD . ( G ) Mycophenylate mofetil ( MMF ) : Administration MMF begin 15 mg/kg po day 0 , 5-10 hour mobilize PBPC infusion complete . Thereafter , begin day +1 MMF take 15 mg/kg po b.i.d . ( 30 mg/kg/day ) transplantation use match related donor 15 mg/kg po t.i.d match unrelated donor one antigen mismatch donor . Doses rounded nearest 250 mg ( capsule 250 mg ) . MMF stop day +28 match related donor one antigen mismatch unrelated donor begin day +40 MMF taper 10 % weekly till , typically day +96 . POST-TRANSPLANT FOLLOW-UP Clinical : The incidence , severity extent acute chronic GVHD monitor score accord standard criterion . As well , document presumed post-transplant infectious complication , rate relapse , event-free overall survival transplant relate mortality record . Assessment Disease Response : Since disease treat protocol heterogenous , appropriate disease specific study perform evaluate response transplant . Responses classify continued complete remission ( CCR ) , achieve complete remission ( CRa ) , partial response ( PR ) , progressive disease ( PD ) , response ( NR ) . Disease response accord accepted criterion . All case progressive disease discuss Principal Investigators . If patient show evidence progressive disease may candidate donor lymphocyte infusion .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>( A ) Any patient one follow hematolymphoid malignancy syndromes allogeneic NST warrant . Specific disease category include : indolent advance stage NonHodgkin Lymphomas , Mantle Cell Lymphoma , Chronic Lymphocytic Leukemia , Hodgkin Disease , Acute Leukemias complete remission , Aplastic Anemia , Paroxsymal Nocturnal Hemoglobinuria , Myelodysplastic Chronic Myeloproliferative Syndromes , Multiple Myeloma . Patients select malignancies/disorders may also consider must approve transplant team Principal Investigator . ( B ) Elderly patient age &gt; 50 &lt; 70 year , patient &lt; 50 year age preexist medical condition prior therapy consider high risk regimenrelated toxicity associate conventional myeloablative transplant , refusal undergo conventional myeloablative regime . ( C ) A fully HLAidentical sibling match unrelated donor available . Patients one antigen mismatch donor consider discussion transplant team Principal Investigator . ( D ) Patient must competent give consent . ( A ) Patients progressive hematolymphoid malignancy despite conventional therapy , acute leukemia complete remission . ( B ) Uncontrolled CNS involvement disease ( C ) Fertile men woman unwilling use contraceptive technique 12 month follow treatment ( D ) Females pregnant ( E ) Organ dysfunction define follow : Cardiac function : ejection fraction &lt; 30 % uncontrolled cardiac failure Pulmonary : DLCO &lt; 40 % predict Liver function abnormality : elevation bilirubin &gt; 3 mg/dl and/or transaminases &gt; 4x upper limit normal Renal : creatinine clearance &lt; 50 cc/min ( 24 hour urine collection ) ( F ) Karnofsky performance score &lt; 60 % ( G ) Patients poorly control hypertension multiple antihypertensive ( H ) Documented fungal disease progressive despite treatment ( I ) Viral infection : HIV positive patient . Hepatitis B C positive patient evaluate case case basis ( J ) Psychiatric disorder psychosocial problem opinion primary physician Principal Investigator would place patient unacceptable risk regimen .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</keyword>
	<keyword>TOTAL LYMPHOID IRRADIATION</keyword>
	<keyword>ANTI-THYMOCYTE GLOBULIN</keyword>
</DOC>